FARAN sa is pleased to announce its collaboration with Japanese Pharmaceutical Company MEIJI in the field of infection diseases with the introduction of Spectracef (ceftidoren pivoxil ) , an original third generation cephalosporin.

Spectracef is a research molecule from MEIJI for the treatment of the respiratory tract infections in the community as well as uncomplicated soft-tissue infections.




FARAN SA and SANDOZ member of the Novartis Group, after their successful collaboration, are pleased to announce the expansion of their cooperation, undertaking the promotion and distribution of another product with the active substance Epoetin alpha.

This collaboration will strengthen the leading position of FARAN SA in Biotechnology, and Sandoz is a World Leader in Research, Development and Production of Biomedicine Drugs.


FARAN SA & NOVARTIS (Hellas) SA collaboration announcement



FARAN SA and NOVARTIS (Hellas) SA are pleased to announce the launch of their collaboration in the field of therapeutic oncology. More specifically, FARAN undertakes the promotion and distribution in the Greek market of the NOVARTIS products TYVERB (Lapatinib) and ZYKADIA (Ceritinib). TYVERB (Lapatinib) is indicated for the treatment of patients with metastatic breast cancer whose tumors over-expresses HER2, while ZYKADIA (Ceritinib) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

This collaboration will strengthen FARAN's leading position in oncology setting among Greek companies, as NOVARTIS is a global leader in research, development and production of innovative drugs. So, FARAN remaining committed to her vision and values, continues to expand its collaboration with esteemed Multinational Pharmaceutical Companies, offering to the Greek patient and health care system, innovative products of High Quality and Therapeutic Value, for the treatment of serious illnesses.


Important Distinction for the Greek Pharmaceutical Company Faran SA



Faran SA, one of the historical Pharmaceutical companies with a presence of more than 70 years in the Greek Pharmaceutical market, received the “2018 Pharmaceutical Sector Business Award” from the Internal Medicine Society of Greece, as an acknowledgement of the continuous contribution of Faran to the Healthcare sector and the public health.

The award was presented by the President of the Internal Medicine Society of Greece, Professor Efstratios Maltezos and the First Vice President, Professor Apostolos Hatzitolios, during the opening ceremony of the 4rth Annual Congress for Continuous Education in Internal Medicine, that was held for the fourth year in Thessaloniki, between 21rst and 25th of February, 2018.